CGON
CG Oncology·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
Significant Net Income Decline
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CGON
Cg Oncology, Inc.
A late-stage clinical biopharmaceutical company focused on treating bladder cancer
400 Spectrum Center Drive, Suite 2040 Irvine, CA 92618
--
CG Oncology, Inc., originally established on September 24, 2010, is a California corporation named Cold Genesys, Inc. On November 30, 2017, the Company was re-registered as a Delaware corporation, and on March 31, 2020, the Company was renamed CG Oncology, Inc. The Company is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder retention therapy for patients with bladder cancer. The company's product candidate, cretostimogene, is initially in clinical development for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC) patients who have not responded to BCG therapy, which is the current standard of care for high-risk NMIBC. Given the limitations of currently approved therapies and the reluctance of patients to undergo radical cystectomy or complete bladder resection, there is a significant unmet need for these patients. The company is evaluating the safety and efficacy of cretostimogene as a monotherapy in BOND-003, and the company is conducting a Phase 3 clinical trial in high-risk BCG non-responsive NMIBC patients. The company has completed enrollment in the trial, reporting interim data in November 2023 and expects to report top-line data by the end of 2024.
Company Financials
EPS
CGON has released its 2025 Q3 earnings. EPS was reported at -0.57, versus the expected -0.55, missing expectations. The chart below visualizes how CGON has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CGON has released its 2025 Q3 earnings report, with revenue of 1.67M, reflecting a YoY change of 3774.42%, and net profit of -43.81M, showing a YoY change of -114.69%. The Sankey diagram below clearly presents CGON's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
